There were numerous articles in April 2017 that covered a wide range of topical issues. Here are five of the best stories you might have missed… (click the headline to finish reading the story)
As the pharmaceutical industry explores new markets, the need for a secure supply chain has never been greater. Today most pharmaceutical companies are expanding into markets in Africa, Latin America, Asia Pacific, and Eastern Europe. Products are becoming more complex with long manufacturing cycles and more stringent shipping conditions. Additionally, the regulatory authorities are focusing more on the supply chain systems, applying guidelines and directives for third parties, such as airlines, freight forwarders and logistics companies.
The other factor is the trend of pharmaceutical high value products being sought after by organized criminal gangs to supply the illegitimate supply chain with lifestyle drugs and those that can be abused, such as painkillers.
You’re in charge of the clinical trial budget at your company. Managing a clinical trial budget comes with great responsibility. Not only do you need to manage costs, there is also lot of pressure to keep expenses low.
This post covers seven advanced strategies to fine tune your clinical trial budget.
Prior to starting any clinical trial, you need to set up a budget that includes all clinical trial costs. Once you’ve created the initial study budget, you’ll need to fine-tune it over the course of the clinical study.
Guess you won’t be too surprised if I tell you that precision medicine is actually an ancient concept. From prehistoric Ayurveda to Hua Tuo in the early era of the first millennium, as well as Hippocrates and his disciples of the Hippocratic School of Medicine (to this day), precision medicine has always been the ultimate goal of medical intervention. Certainly, it helps that former US President Barack Obama’s administration brought precision medicine to the national (and global) attention as a modern day health care platform in an era of patient centricity (fingers crossed for the next four years).
510K approval and initial acceptance by a small group of interested physicians may only be the first step toward widespread use and for making the case for reimbursement, leading wider market acceptance. Oftentimes, device marketers hear physicians say, “I will only accept data from a Randomized Controlled Clinical study of this device.”This sentiment is largely based on a belief that an RCT is the gold standard and other study designs are inferior. An RCT can generate reliable, high quality data, but how much better are they compared to prospective or retrospective observational studies?
Within the pharmaceutical industry, packaging for medicinal products is a lucrative business. According to a recent report, pharmaceutical packaging will be worth $94.93 billion by 2021, indicating the grand scale of the market.
Recently, CTA ’s Henry Kerali sat down with Andrew Streeter, packaging innovation director, GlobalData. With a wealth of experience working in the packaging industry, Streeter is well placed to ascertain emerging trends within the market and its overall impact.
In this wide-ranging interview, Streeter discusses pharma’s use of intelligent packaging, shedding a light on the issues and opportunities that lie in wait with for the industry.
PHOTO CREDIT: Rob Nguyen